98%
921
2 minutes
20
Objectives: To make informed decisions, the general population should have access to accessible and understandable health recommendations. To compare understanding, accessibility, usability, satisfaction, intention to implement, and preference of adults provided with a digital "Plain Language Recommendation" (PLR) format vs. the original "Standard Language Version" (SLV).
Study Design And Setting: An allocation-concealed, blinded, controlled superiority trial and a qualitative study to understand participant preferences. An international on-line survey. 488 adults with some English proficiency. 67.8% of participants identified as female, 62.3% were from the Americas, 70.1% identified as white, 32.2% had a bachelor's degree as their highest completed education, and 42% said they were very comfortable reading health information. In collaboration with patient partners, advisors, and the Cochrane Consumer Network, we developed a plain language format of guideline recommendations (PLRs) to compare their effectiveness vs. the original standard language versions (SLVs) as published in the source guideline. We selected two recommendations about COVID-19 vaccine, similar in their content, to compare our versions, one from the World Health Organization (WHO) and one from Centers for Disease Control and Prevention (CDC). The primary outcome was understanding, measured as the proportion of correct responses to seven comprehension questions. Secondary outcomes were accessibility, usability, satisfaction, preference, and intended behavior, measured on a 1-7 scale.
Results: Participants randomized to the PLR group had a higher proportion of correct responses to the understanding questions for the WHO recommendation (mean difference [MD] of 19.8%, 95% confidence interval [CI] 14.7-24.9%; P < 0.001) but this difference was smaller and not statistically significant for the CDC recommendation (MD of 3.9%, 95% CI -0.7% to 8.3%; P = 0.096). However, regardless of the recommendation, participants found the PLRs more accessible, (MD of 1.2 on the seven-point scale, 95% CI 0.9-1.4%; P < 0.001) and more satisfying (MD of 1.2, 95% CI 0.9-1.4%; P < 0.001). They were also more likely to follow the recommendation if they had not already followed it (MD of 1.2, 95% CI 0.7-1.8%; P < 0.001) and share it with other people they know (MD of 1.9, 95% CI 0.5-1.2%; P < 0.001). There was no significant difference in the preference between the two formats (MD of -0.3, 95% CI -0.5% to 0.03%; P = 0.078). The qualitative interviews supported and contextualized these findings.
Conclusion: Health information provided in a PLR format improved understanding, accessibility, usability, and satisfaction and thereby has the potential to shape public decision-making behavior.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.jclinepi.2023.11.009 | DOI Listing |
J Healthc Sci Humanit
January 2024
Director, Northern Plains Ethics Institute, Editor, Springer's International Library of Bioethics, Professor of Philosophy and Ethics, History, Philosophy, and Religious Studies-Dept. 2340, Minard Hall 422J, P.O Box 6050, North Dakota State University, Fargo, ND 58108, [701] 231-7038, Email: dennis.
The USA's COVID-19 pandemic experience is an example of privileged thinking that what generally works for those in power ought to be the standard for what makes medical interventions, research, treatments, and policy ethical. As a result of not focusing on doing whatever was required for vulnerable or susceptible populations or their members to achieve their health and flourishing, there are a disproportionate numbers of COVID-19 infections and deaths in Black, Hispanic, and indigenous communities. Future studies will likely show even more harm and larger health failure than known of now.
View Article and Find Full Text PDFInquiry
September 2025
Duke University, Durham, NC, USA.
Although critical to enacting change, effectively communicating clinical and public health research results remains a challenge. In a webinar that occurred on December 7, 2023, a group of clinical and public health researchers and communications specialists convened to share their experiences using plain language materials to communicate research results. Herein, they provide practical guidance and case examples of lay summaries, infographics, data dashboards, and zines, along with challenges and potential solutions.
View Article and Find Full Text PDFEndocr Connect
September 2025
Department of Paediatric Endocrinology, Alder Hey Children's NHS Foundation Trust, Liverpool, UK.
Background: Limited data are available on the growth response to growth hormone (GH) treatment of very young children with GH deficiency (GHD). In the present analysis, we compared clinical outcomes after GH treatment in children with GHD aged <2 and ≥2 years at the start of GH treatment.
Methods: We analysed pooled data from two observational studies of paediatric patients who received Norditropin® treatment: NordiNet® IOS (NCT00960128) and the ANSWER Program (NCT01009905).
Cancer Med
September 2025
Department of Biostatistics & Data Science, School of Public and Population Health, University of Texas Medical Branch, Galveston, Texas, USA.
Introduction: Chronic pain is a major but modifiable contributor to poor quality of life among long-term cancer survivors. With growing concern over opioid-related risks, gabapentinoids have emerged as a safer alternative, though evidence comparing their effectiveness remains limited.
Methods: We conducted a retrospective cohort study using SEER-MHOS linked data (1998-2021) to examine pain interference and health-related quality of life (HRQoL) among 24,651 cancer survivors.
Diabetes Obes Metab
September 2025
Eli Lilly and Company, Indianapolis, Indiana, USA.
Aims: To determine whether adults with type 2 diabetes (T2D) treated with retatrutide report greater changes in self-reported appetite, dietary restraint, and disinhibition compared to placebo or dulaglutide and to examine associations with weight change.
Materials And Methods: These pre-specified exploratory analyses examined changes from baseline in Appetite Visual Analogue Scale (VAS) and Eating Inventory (EI) scores after 24 and 36 weeks of once-weekly treatment with placebo, dulaglutide 1.5 mg, or retatrutide 0.